As GLP-1 drugs transition from diabetes treatment to widespread weight management tools, experts question the safety of prolonged use and highlight barriers due to high costs and unregulated alternatives, prompting calls for sustained medical oversight.
GLP-1 medicines have moved rapidly from specialist diabetes treatment to a cultural obsession, yet the biggest question surrounding them is still unresolved: what happens when people use them for years rather than months? The Seattle Times reported that the drugs, originally developed to help control type 2 diabetes, are now being used by an estimated 11% of US adults for weight loss, with some patients also turning to unregulated “grey market” versions because of cost and access problems.
At their core, GLP-1s mimic a natural hormone that helps regulate blood sugar and signals fullness after eating. Dr Jaime Almandoz of UT Southwestern Medical Center told the Seattle Times that they can leave people feeling satisfied on less food for longer, which helps explain why they have become a major tool for both diabetes treatment and chronic weight management. The first drug in the class was approved by the US Food and Drug Administration in 2005 for type 2 diabetes, and the first weight-loss version followed nine years later.
The short-term benefits are increasingly well established, but the longer view is more complicated. The Seattle Times cited the 2023 SELECT trial, which found a 20% average reduction in major cardiovascular events among obese participants taking semaglutide. Yet research and clinical guidance also point to common side effects such as nausea, vomiting, diarrhoea and constipation, with less common but more serious risks including pancreatitis, gallbladder problems and allergic reactions, according to Yale Medicine. Health experts also continue to monitor possible links to kidney injury and thyroid-related concerns, although the strength of those risks can vary by drug and patient profile.
One emerging concern is what happens when treatment stops. Axios reported this week that new research is adding to evidence that discontinuation may carry consequences beyond simple weight regain, including a higher risk of heart attack, stroke and death in some patients who stopped GLP-1 treatment for two years. The report also noted findings tying early discontinuation to higher risks of heart failure and coronary artery disease, suggesting that the metabolic benefits may fade quickly once the medicine is withdrawn. That has made some researchers and drugmakers more focused on whether the gains from these medicines can be maintained after treatment ends.
Cost and access remain another major obstacle. The Seattle Times said a Cleveland Clinic study last year found that nearly half of patients who stopped using GLP-1 drugs did so for financial reasons, while University of Chicago Medicine estimates put monthly costs at roughly $700 to $800. That price barrier has helped fuel demand for unofficial alternatives, but experts warn that off-market versions may not meet safety or quality standards. Almandoz and Sarah Messiah of UT Southwestern both argued that the drugs should be used with medical supervision and as part of a broader plan that includes diet and exercise, rather than as a shortcut to the lowest possible number on the scales.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
